Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Augmentin ES-600 Label Places Limit On Use For Penicillin-Resistant Strains

Executive Summary

GlaxoSmithKline's Augmentin ES-600 labeling for otitis media sets a limit on the S. pneumoniae penicillin-resistant strains the antibiotic is expected to effectively treat.

You may also be interested in...



GSK’s X-Factor: Augmentin XR, Other Line Extensions Key To Growth

GSK hopes that it can hold on to more than half of its Augmentin franchise with the XR and ES line extensions

GSK’s X-Factor: Augmentin XR, Other Line Extensions Key To Growth

GSK hopes that it can hold on to more than half of its Augmentin franchise with the XR and ES line extensions

GSK Augmentin ES Conversion Rate Reaches 31%; XR Filing Imminent

GlaxoSmithKline is converting about one-third of Augmentin suspension Rxs to the ES-600 formulation, GSK Chief Operating Officer Bob Ingram told securities analysts Feb. 14

Related Content

UsernamePublicRestriction

Register

PS038102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel